Search
Displaying 71–80 of 543 for “Retinitis pigmentosa”
-
Foundation News
Innovative Ways to Support Research for Treatments and Cures for Blinding Diseases
-
Eye on the Cure Podcast | Episode 69: Dr. Francois Paquet-Durand
Eye on the CureFrancois Paquet-Durand, PhD, a professor from the University of Tübingen and co-founder of the company Mireca, talks to host Ben Shaberman about the long journey of an emerging, Foundation-funded drug for the treatment of certain forms of retinitis pigmentosa. The episode highlights the challenges that scientists often encounter when developing a drug for a retinal disease, and the persistence and tenacity that are required to keep it moving forward.
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Eye on the Cure Podcast | Episode 68: Dr. Michael Telias
Eye on the CureFor this episode of Eye on the Cure, Michael Telias, PhD, an assistant professor at the University of Rochester in New York, talks with host Ben Shaberman about forthcoming clinical trials to evaluate the FDA-approved drug disulfiram (aka, Antabuse) for improving vision in people with retinitis pigmentosa and other retinal diseases. Disulfiram was originally developed to deter people from abusing alcohol.
-
Karen Petrou Appointed as Board Chair of the Foundation Fighting Blindness
Foundation NewsDavid Brint retires after eight years of distinguished service; Petrou to lead effective July 1, 2024.
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Foundation News
Advancing Research Solutions for PRPH2-Associated Retinal Diseases.
-
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Research NewsMutations in PDE6B are a leading cause of retinitis pigmentosa.
-
VISIONS 2024, the global conference (June 20–21, 2024) of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
What Does “Blindness” Really Mean?
Beacon StoriesJenny Schisler has retinitis pigmentosa. Jenny wants to spread awareness of what having a visual impairment really means to her and others affected by retinal degenerative diseases.
.png)
